Oscar Health Inc vs Zimmer Biomet Holdings Inc — how do they compare? Oscar Health Inc trades at $28.9 (market cap $9.28B), while Zimmer Biomet Holdings Inc trades at $88.69 (market cap $17.20B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals.
| OSCR | ZBH | |
|---|---|---|
Market Cap | $9.28B | $17.20B |
Sector | Health | Health |
52-Week High | $32.18 | $107.71 |
52-Week Low | $10.85 | $79.58 |
Enterprise Value | $4.90B | $24.25B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
Oscar Health (OSCR) trades at $29.60, up 1.72% with mixed technical signals showing neutral overall momentum. The company reported strong Q1 2026 earnings beat but faces profitability challenges with negative margins. Revenue growth from $11.7B in 2025 to projected $13.3B in 2026 indicates expansion, while cash flow trends show operational improvement. Analyst consensus is divided with 27% buy ratings against a $24.67 price target below current levels.
The stock presents growth potential through revenue expansion and cash flow generation, but profitability concerns and negative ROE pose significant risks. Current valuation at 0.61 P/S suggests reasonable pricing for growth, though execution on margin improvement remains critical for sustained upside.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →